PUBLISHER: The Business Research Company | PRODUCT CODE: 1945344
PUBLISHER: The Business Research Company | PRODUCT CODE: 1945344
Immunofluorescence assay encompasses both equipment and consumables designed to utilize a technique allowing the visualization of specific proteins and antigens in infected cells. This visualization is achieved through the reaction of these proteins and antigens with specific antibodies, which are chemically conjugated with a fluorescent dye. This laboratory technique is employed in the diagnosis of diseases affecting various organ systems such as the skin, kidney, heart, cilia, and others.
The main types of immunofluorescence assay include direct immunofluorescence and indirect immunofluorescence. Direct immunofluorescence is a laboratory technique specifically used for diagnosing diseases related to the skin, kidney, and other organ systems. In this method, a single antibody directly conjugated to a fluorescent dye is utilized. The diverse range of products in the immunofluorescence assay category includes reagents, instruments, antibodies, kits, consumables, and accessories. These products are employed in the diagnosis of various diseases, including cancer, infectious diseases, autoimmune diseases, among others. Immunofluorescence assay products are utilized by academic and research institutions, pharmaceutical and biotechnology companies, hospitals and diagnostic centers, as well as contract research organizations.
Tariffs are impacting the immunofluorescence assay market by increasing costs of imported antibodies, fluorescent dyes, imaging instruments, and laboratory automation equipment. Research institutions and diagnostic laboratories in North America and Europe are most affected due to reliance on specialized imports, while Asia-Pacific faces cost pressure on assay kit manufacturing. These tariffs are raising operational costs and slowing procurement cycles. However, they are also encouraging regional reagent production, local instrument assembly, and innovation in cost-efficient assay development.
The immunofluorescence assay market research report is one of a series of new reports from The Business Research Company that provides immunofluorescence assay market statistics, including immunofluorescence assay industry global market size, regional shares, competitors with a immunofluorescence assay market share, detailed immunofluorescence assay market segments, market trends and opportunities, and any further data you may need to thrive in the immunofluorescence assay industry. This immunofluorescence assay market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The immunofluorescence assay market size has grown rapidly in recent years. It will grow from $3.56 billion in 2025 to $3.94 billion in 2026 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to expansion of laboratory diagnostic testing, increasing use of immunoassays in disease detection, growth in academic and clinical research activities, advancements in fluorescence labeling technologies, rising adoption of antibody-based diagnostics.
The immunofluorescence assay market size is expected to see rapid growth in the next few years. It will grow to $5.89 billion in 2030 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to growing demand for precision diagnostics, rising investments in translational research, expansion of personalized medicine approaches, increasing automation in laboratory workflows, advancements in imaging and data analysis software. Major trends in the forecast period include increasing adoption of multiplex immunofluorescence assays, rising use of automated imaging and analysis systems, growing demand for high-sensitivity diagnostic reagents, expansion of immunofluorescence applications in oncology, enhanced focus on standardized and reproducible testing.
The robust growth of the immunofluorescence assay market is significantly attributed to the increasing prevalence of chronic diseases. Lifestyle changes, dietary habits, and inadequate weight management contribute to a surge in chronic conditions, with prolonged infections posing a risk of developing cancer. Immunofluorescence assays are witnessing heightened demand for their extensive use in the diagnosis and drug development activities associated with chronic diseases. For instance, in January 2025,according to the PubMed Central, a US based free digital repository that archives full-text biomedical and life sciences journal articles, reported that as individuals live longer, the prevalence and cost of chronic disease continue to grow. The estimated cost of chronic disease is expected to reach $47 trillion worldwide by 2030. Therefore, the escalating prevalence of chronic diseases is anticipated to drive the demand for immunofluorescence assays throughout the forecast period.
Major players in the immunofluorescence assay market are strategically focusing on introducing fully automated solutions to maximize their market revenues. Fully automated solutions streamline the entire immunofluorescence testing process, from sample preparation to incubation, washing, and slide mounting. Revvity Inc., a US-based life sciences and diagnostics company, launched UNIQO 160 (CE-IVDR), an automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics in June 2023. UNIQO 160, a tabletop device, integrates automated processing with a high-quality microscope, capable of handling up to 160 main samples and 18 slides in a single run. The system utilizes barcode recognition for individual samples, reagents, and slides.
In April 2024, Merck KGaA, a Germany-based life sciences and diagnostics company, entered into a partnership with Miltenyi Biotec to co-develop high-plex immunofluorescence reagents and imaging solutions. Through this collaboration, both companies aim to improve the performance and accessibility of immunofluorescence assays for biomarker profiling and spatial biology applications in research and clinical laboratories by combining expertise in reagents, imaging technologies, and single-cell analysis. Miltenyi Biotec is a Germany-based company that specializes in cell separation technologies, single-cell analysis solutions, and immunofluorescence assays.
Major companies operating in the immunofluorescence assay market are Thermo Fisher Scientific Inc., Abcam plc, Bio-Rad Laboratories Inc., PerkinElmer Inc., Werfen Company, Merck KGaA, Danaher Corporation, Cell Signaling Technology Inc., Vector Laboratories Inc., INOVA Diagnostics Inc., Sino Biological Inc., Medipan GmbH, BioLegend Inc., Jackson ImmunoResearch Laboratories Inc., Rockland Immunochemicals Inc., Bethyl Laboratories Inc., Fitzgerald Industries International Inc., Creative Diagnostics, Boster Biological Technology, Acris Antibodies GmbH, RayBiotech Inc., Proteintech Group Inc., Novus Biologicals LLC, R&D Systems Inc., OriGene Technologies Inc., GenScript Biotech Corporation, MBL International Corporation, Abnova Corporation, Cellabs India Technologies Limited, J. Mitra & Co. Pvt. Ltd., EpiGentek Group Inc., Elabscience Biotechnology Co. Ltd., Aesku.Diagnostics GmbH
North America was the largest region in the immunofluorescence assay market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunofluorescence assay market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the immunofluorescence assay market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The immunofluorescence assay market consists of sales of indirect IF complement-fixation (IF-CF), and double IF. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Immunofluorescence Assay Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses immunofluorescence assay market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for immunofluorescence assay ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The immunofluorescence assay market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.